Exchange & Returns Information
Review Details
(0)
| Drug Type | Original |
|---|---|
| Active Ingredient | IPILIMUMAB |
| Strength | 50MG |
| Manufacturer | BRISTOL MYERS SQUIBB |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 1,240.00 | $ 1,240.00 |
$ 1,054.00
Apply ZARVY26 (-15%)
You save $ 186.00
|
||
| 2 BOXES - 2 VIALS | $ 1,210.00 |
2% $ 2,480.00
$ 2,420.00
|
$ 2,057.00
Apply ZARVY26 (-15%)
You save $ 363.00
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 1,165.00 |
6% $ 3,720.00
$ 3,495.00
|
$ 2,970.75
Apply ZARVY26 (-15%)
You save $ 524.25
|
Reference information will be available soon.
Yervoi 50mg, Solution for Injection contains Ipilimumab, a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). As a checkpoint inhibitor, it enhances antitumor immunity by sustaining T-cell activation and proliferation. Ipilimumab is a critical component of combination immunotherapy regimens, particularly with Nivolumab, for various malignancies. It is widely used in both metastatic and adjuvant settings across melanoma, renal cell carcinoma, colorectal cancer, NSCLC, and other cancer types.
AntiCancer Drugs > Skin Cancer (Melanoma)
Indicated for unresectable or metastatic melanoma, as well as adjuvant treatment in high-risk resected cases. By blocking CTLA-4, Ipilimumab promotes sustained T-cell mediated destruction of melanoma cells.
Lung Cancer (NSCLC, Mesothelioma)
Used in combination with Nivolumab and platinum-doublet chemotherapy for first-line treatment of metastatic NSCLC and malignant pleural mesothelioma, improving progression-free survival and durable response rates.
Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Cancer
Ipilimumab plus Nivolumab offers a checkpoint blockade regimen in PD-L1 positive or recurrent/metastatic HNSCC and advanced esophageal squamous cell carcinoma, especially after prior therapy.
Liver Cancer (Hepatocellular Carcinoma)
Used post-sorafenib in patients with advanced HCC. The combination with Nivolumab restores antitumor immunity by targeting multiple immune checkpoints.
Kidney Cancer (Renal Cell Carcinoma)
Indicated as first-line therapy in combination with Nivolumab for advanced RCC. Enhances tumor rejection in intermediate- and poor-risk patients.
Colorectal Cancer (MSI-H/dMMR)
Approved for metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer, offering durable disease control after chemotherapy failure.
Others (Pediatric Melanoma and mCRC, Off-label Solid Tumors)
Used in adolescents ≥12 years with advanced melanoma or mCRC. Emerging studies support use in refractory or biomarker-positive malignancies.
Melanoma: Monotherapy: 3 mg/kg IV every 3 weeks × 4 doses. Combo: 3 mg/kg IV q3w × 4 doses with Nivolumab (or until toxicity). Adjuvant: 10 mg/kg IV q3w × 4 doses, then q12w up to 3 years.
Renal Cell Carcinoma: 1 mg/kg IV q3w × 4 doses with Nivolumab 3 mg/kg.
Colorectal Cancer (MSI-H/dMMR): 1 mg/kg IV q3w × 4 doses + Nivolumab.
Hepatocellular Carcinoma: 3 mg/kg IV q3w × 4 doses + Nivolumab 1 mg/kg.
NSCLC: 1 mg/kg IV q6w with Nivolumab 360 mg q3w + 2 cycles of chemotherapy.
Malignant Pleural Mesothelioma: 1 mg/kg IV q6w + Nivolumab 360 mg q3w.
Esophageal SCC: 1 mg/kg IV q6w + Nivolumab q2w or q3w.
Pediatric (≥12 yrs): Melanoma: 3 mg/kg IV q3w × 4 doses (mono or with Nivolumab 1 mg/kg). mCRC: 1 mg/kg IV q3w × 4 doses + Nivolumab 3 mg/kg.
All infusions should be administered over 30 minutes. Therapy may continue with Nivolumab monotherapy after the Ipilimumab phase. Confirm PD-L1, MSI, or BRAF status as per indication-specific requirements.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
